Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

Stock Information for Sol-Gel Technologies Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sol-Gel Technologies Ltd.

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Announces Health Canada Approval of EPSOLAY®
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Reports First Quarter 2025 Results
Sol-Gel Announces Reverse Share Split
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.